Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
07:00am, Tuesday, 11'th Mar 2025
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast
3 Top Cancer Biotechs to Keep An Eye On in 2025
09:25am, Friday, 07'th Mar 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
07:00am, Monday, 24'th Feb 2025
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN
08:26pm, Sunday, 16'th Feb 2025
One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partn
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 06'th Jan 2025
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
08:50am, Monday, 23'rd Dec 2024
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
07:00am, Friday, 13'th Dec 2024
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an
BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degr
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
06:45pm, Monday, 02'nd Dec 2024
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
07:00am, Tuesday, 26'th Nov 2024
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
11:00am, Friday, 15'th Nov 2024
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
09:35am, Thursday, 07'th Nov 2024
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.70 per share a year ago.
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice
01:05pm, Wednesday, 06'th Nov 2024
Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
